Virginia Giuliani - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Virginia Giuliani

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

Cancer Research|September 15, 2020

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward OsimertinibYuting Sun, Brooke A Meyers, Barbara Czako, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor TypesPatrick G Pilié, Virginia Giuliani, Wei-Lien Wang, et al.

Nature Medicine|June 13, 2018

An inhibitor of oxidative phosphorylation exploits cancer vulnerabilityJennifer R Molina, Yuting Sun, Marina Protopopova, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

Cancer Research|September 15, 2020

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward OsimertinibYuting Sun, Brooke A Meyers, Barbara Czako, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor TypesPatrick G Pilié, Virginia Giuliani, Wei-Lien Wang, et al.

Nature Medicine|June 13, 2018

An inhibitor of oxidative phosphorylation exploits cancer vulnerabilityJennifer R Molina, Yuting Sun, Marina Protopopova, et al.

Pageof 3